Windtree Therapeutics Engages Strategic Adviser to Evaluate Options for Cardiovascular Portfolio; Shares Fall

MT Newswires Live12-05

Windtree Therapeutics (WINT) said Wednesday it has tapped New Growth Advisors as its strategic adviser to lead a potential transaction process for its cardiovascular portfolio.

New Growth Advisors will help manage the current inbound interest and run an expanded out-licensing process for the portfolio, Windtree said.

The company said it's looking to secure potentially non-dilutive financing through a partnership for istaroxime and the oral SERCA2a activators for all global territories excluding Greater China.

In Greater China, Windtree has a licensing deal for istaroxime, dual mechanism SERCA2a activators and rostafuroxin with Lee's Pharmaceuticals for which it could receive as much as $138 million in potential milestones and low-double-digit royalties.

Windtree said Lee's expects to launch phase 3 in acute heart failure in its licensed territory in H1 2025.

Windtree shares were down 13.5% in recent trading.

Price: 0.47, Change: -0.07, Percent Change: -13.52

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2489111662?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-12-05 00:47","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2489111662","market":"hk","top_or_hot":-1,"title":"Windtree Therapeutics Engages Strategic Adviser to Evaluate Options for Cardiovascular Portfolio; Shares Fall","media":"MT Newswires Live","content":"<html><body><p> Windtree <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (WINT) said Wednesday it has tapped New Growth Advisors as its strategic adviser to lead a potential transaction process for its cardiovascular portfolio.</p><p>New Growth Advisors will help manage the current inbound interest and run an expanded out-licensing process for the portfolio, Windtree said.</p><p>The company said it's looking to secure potentially non-dilutive financing through a partnership for istaroxime and the oral SERCA2a activators for all global territories excluding Greater China.</p><p>In Greater China, Windtree has a licensing deal for istaroxime, dual mechanism SERCA2a activators and rostafuroxin with Lee's Pharmaceuticals for which it could receive as much as $138 million in potential milestones and low-double-digit royalties.</p><p>Windtree said Lee's expects to launch phase 3 in acute heart failure in its licensed territory in H1 2025.</p><p>Windtree shares were down 13.5% in recent trading.</p><p>Price: 0.47, Change: -0.07, Percent Change: -13.52</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Windtree Therapeutics Engages Strategic Adviser to Evaluate Options for Cardiovascular Portfolio; Shares Fall</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWindtree Therapeutics Engages Strategic Adviser to Evaluate Options for Cardiovascular Portfolio; Shares Fall\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-12-05 00:47 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.mtnewswires.com/><strong>MT Newswires Live</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Windtree Therapeutics (WINT) said Wednesday it has tapped New Growth Advisors as its strategic adviser to lead a potential transaction process for its cardiovascular portfolio.New Growth Advisors will...</p>\n\n<a href=\"https://www.mtnewswires.com/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2489111662","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2489111662","pubTimestamp":1733330822,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Windtree Therapeutics  said Wednesday it has tapped New Growth Advisors as its strategic adviser to lead a potential transaction process for its cardiovascular portfolio.New Growth Advisors will help manage the current inbound interest and run an expanded out-licensing process for the portfolio, Windtree said.The company said it's looking to secure potentially non-dilutive financing through a partnership for istaroxime and the oral SERCA2a activators for all global territories excluding Greater China.In Greater China, Windtree has a licensing deal for istaroxime, dual mechanism SERCA2a activators and rostafuroxin with Lee's Pharmaceuticals for which it could receive as much as $138 million in potential milestones and low-double-digit royalties.Windtree said Lee's expects to launch phase 3 in acute heart failure in its licensed territory in H1 2025.Windtree shares were down 13.5% in recent trading.Price: 0.47, Change: -0.07, Percent Change: -13.52","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","WINT":"Windtree Therapeutics, Inc.","CSII":"Cardiovascular Systems","LENZ":"Therapeutics","BK4082":"医疗保健设备"},"translate_title":"Windtree Therapeutics聘请战略顾问评估心血管产品组合的选择；股价下跌","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CSII":1,"LENZ":1,"WINT":0.9},"content_text":"Windtree Therapeutics (WINT) said Wednesday it has tapped New Growth Advisors as its strategic adviser to lead a potential transaction process for its cardiovascular portfolio.New Growth Advisors will help manage the current inbound interest and run an expanded out-licensing process for the portfolio, Windtree said.The company said it's looking to secure potentially non-dilutive financing through a partnership for istaroxime and the oral SERCA2a activators for all global territories excluding Greater China.In Greater China, Windtree has a licensing deal for istaroxime, dual mechanism SERCA2a activators and rostafuroxin with Lee's Pharmaceuticals for which it could receive as much as $138 million in potential milestones and low-double-digit royalties.Windtree said Lee's expects to launch phase 3 in acute heart failure in its licensed territory in H1 2025.Windtree shares were down 13.5% in recent trading.Price: 0.47, Change: -0.07, Percent Change: -13.52","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2489111662"}